Aethlon Medical Reports Q3 Net Loss of $2.02 Million, Advances Hemopurifier Clinical Trial

Aethlon Medical, Inc. reported its financial results for the three and nine months ended December 31, 2025, revealing a net loss of approximately $2.02 million for the quarter, compared to a loss of $1.75 million in the same period last year. For the nine-month period, the company recorded a net loss of about $5.27 million, down from $7.13 million in the prior year. The basic and diluted loss per share for the latest quarter was $(2.45), a significant improvement from $(10.05) in the previous year, reflecting a reduction in the number of shares outstanding due to a reverse stock split implemented in October 2025.

Total operating expenses for the three months increased by 13.6% to approximately $2.06 million, primarily driven by a $367,000 rise in payroll and related expenses. This increase was partially offset by a decrease in general and administrative expenses, which fell by about $75,000, and a reduction in professional fees. For the nine-month period, operating expenses decreased by 26.9% to approximately $5.36 million, attributed to lower payroll costs, general and administrative expenses, and professional fees, which collectively dropped by nearly $1.97 million compared to the previous year.

In terms of strategic developments, Aethlon Medical is advancing its Hemopurifier® device, which has received FDA designation as a "Breakthrough Device" for treating advanced cancer and life-threatening viral infections. The company is currently conducting a clinical trial in Australia, with three sites open for enrollment. The trial aims to evaluate the safety and feasibility of the Hemopurifier in patients with solid tumors. Following a successful review by the Data Safety Monitoring Board, the company has begun enrolling participants for the second cohort of the trial.

Aethlon Medical's financial position has improved, with total assets increasing to approximately $8.06 million as of December 31, 2025, compared to $7.36 million at the end of the previous fiscal period. Cash and cash equivalents rose to $6.96 million, up from $5.50 million. The company also reported a significant reduction in current liabilities, which decreased to approximately $1.26 million from $1.90 million. However, the company noted that existing cash may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern without securing additional capital.

Looking ahead, Aethlon Medical is actively exploring various financing options to extend its cash runway and support ongoing clinical development activities. The company is also monitoring external factors such as inflation and geopolitical events that may impact its operations and access to capital. The successful outcomes of its clinical trials will be crucial for future regulatory approvals and market entry of the Hemopurifier, as well as for the company's overall financial health.